Mayne Pharma provides update on 1Q FY24 trading and outlook
Filed with ASX · · 28 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call• Initiated program of cost and efficiency initiatives across the Group with ~ US$10 million identified and executed during 1H 24 to drive sustainable improvement in EBITDA • Key priority is delivering growth and returns from existing portfolio, with no plans to deploy capital on acquisitions • Mayne Pharma will seek shareholder approval at the Annual General Meeting to increase its current on-mar
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- 2023 Full Year Results Investor Presentation
- 2023 Full Year Results Media Release
- Preliminary Final Report
- MYX provides investor update & announces on market buyback
- Mayne Pharma May 2023 market update presentation
Later from Mayne Pharma
- Mayne Pharma provides update on first quarter 2024 trading and outlook
- Issuance of additional US Patent for NEXTSTELLIS
- Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- 2024 Half Year Investor Presentation
- 2024 Half Year Media Release
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma